Fungal colonization of haematological patients receiving cytotoxic chemotherapy : emergence of azole-resistant Saccharomyces cerevisiae

Fungal colonization during cytotoxic chemotherapy was studied in 42 patients with a recent diagnosis of a haematological malignancy. In total, 2759 surveillance cultures were taken from the nostrils, throat, urine, stool and perineal region. Seven hundred and ninety-six positive surveillance culture...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of hospital infection 2000-08, Vol.45 (4), p.293-301
Hauptverfasser: SALONEN, J. H, RICHARDSON, M. D, GALLACHER, K, ISSAKAINEN, J, HELENIUS, H, LEHTONEN, O.-P, NIKOSKELAINEN, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 301
container_issue 4
container_start_page 293
container_title The Journal of hospital infection
container_volume 45
creator SALONEN, J. H
RICHARDSON, M. D
GALLACHER, K
ISSAKAINEN, J
HELENIUS, H
LEHTONEN, O.-P
NIKOSKELAINEN, J
description Fungal colonization during cytotoxic chemotherapy was studied in 42 patients with a recent diagnosis of a haematological malignancy. In total, 2759 surveillance cultures were taken from the nostrils, throat, urine, stool and perineal region. Seven hundred and ninety-six positive surveillance cultures (28.9%) yielded 968 fungal isolates. The rate of fungal colonization did not differ between patients with acute leukaemia, patients with other haematological malignancies and control patients in the same ward at admission (71% vs. 67% vs. 80%). Patients with acute leukaemia were colonized at a significantly lower rate in samples from the throat (32%), urine (10%), stool (45%) and perineum (29%) taken during hospitalization when compared with other haematological patients (respective values 58%, 21%, 67% and 45%; P-values 0.001). This could be attributed to differences in the use of antifungal drugs. Although 21/42 (50%) of our patients had multiple-site fungal colonization at the end of follow-up, only one systemic Candida infection was diagnosed. Extensive use of antifungal treatment may have influenced the low incidence of systemic fungal infections during the follow-up. In addition to Candida species, Malassezia furfur, Geotrichum candidum and Saccharomyces cerevisiae were frequently isolated. The rate of S. cerevisiae isolation increased significantly over time after admission (1%, vs. 18% of isolates, P
doi_str_mv 10.1053/jhin.1999.0718
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17868070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17868070</sourcerecordid><originalsourceid>FETCH-LOGICAL-p267t-6b33a90d88ad3febf0461ddbcbb4f40ab551cf8e4d9bb5479aa83e744ecd7763</originalsourceid><addsrcrecordid>eNpFkLFu2zAURYkiReO4XTMGHIJuckmTEsVsgRE3BQx0qHfjkXqyaEikQtJB7B_ob1dFHXS6wLkHd7iE3HK24KwU3w6d8wuutV4wxesPZMZLsSyWWugrMmNcl0WlGL8mNykdGGMTLz-Ra860EkqqGfm9Pvo99NSGPnh3huyCp6GlHeAAeYJ7Z6d6nAr0OdGIFt2r83tqTznk8OYstR0OIXcYYTzRB4oDxj16i3934Bx6LCImlzL4TH-BtR3EMJwsJmox4qtLDvAz-dhCn_DLJedku37arp6Lzc_vP1aPm2JcVioXlRECNGvqGhrRommZrHjTGGuMbCUDU5bctjXKRhtTSqUBaoFKSrSNUpWYk6__ZscYXo6Y8m5wyWLfg8dwTDuu6qpmik3i3UU8mgGb3RjdAPG0e39uEu4vAqTpoTaCty7996RmeinEH1rvgmk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17868070</pqid></control><display><type>article</type><title>Fungal colonization of haematological patients receiving cytotoxic chemotherapy : emergence of azole-resistant Saccharomyces cerevisiae</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>SALONEN, J. H ; RICHARDSON, M. D ; GALLACHER, K ; ISSAKAINEN, J ; HELENIUS, H ; LEHTONEN, O.-P ; NIKOSKELAINEN, J</creator><creatorcontrib>SALONEN, J. H ; RICHARDSON, M. D ; GALLACHER, K ; ISSAKAINEN, J ; HELENIUS, H ; LEHTONEN, O.-P ; NIKOSKELAINEN, J</creatorcontrib><description>Fungal colonization during cytotoxic chemotherapy was studied in 42 patients with a recent diagnosis of a haematological malignancy. In total, 2759 surveillance cultures were taken from the nostrils, throat, urine, stool and perineal region. Seven hundred and ninety-six positive surveillance cultures (28.9%) yielded 968 fungal isolates. The rate of fungal colonization did not differ between patients with acute leukaemia, patients with other haematological malignancies and control patients in the same ward at admission (71% vs. 67% vs. 80%). Patients with acute leukaemia were colonized at a significantly lower rate in samples from the throat (32%), urine (10%), stool (45%) and perineum (29%) taken during hospitalization when compared with other haematological patients (respective values 58%, 21%, 67% and 45%; P-values 0.001). This could be attributed to differences in the use of antifungal drugs. Although 21/42 (50%) of our patients had multiple-site fungal colonization at the end of follow-up, only one systemic Candida infection was diagnosed. Extensive use of antifungal treatment may have influenced the low incidence of systemic fungal infections during the follow-up. In addition to Candida species, Malassezia furfur, Geotrichum candidum and Saccharomyces cerevisiae were frequently isolated. The rate of S. cerevisiae isolation increased significantly over time after admission (1%, vs. 18% of isolates, P&lt;0.001), suggesting hospital-acquired transmission. These isolates were highly resistant to azole antifungals (MIC90 128 microg/mL for fluconazole and 16 microg/ml, for itraconazole), and caused persistent multiple site colonization in 12 patients. Extensive use of antifungal agents in a haematological ward may keep the incidence of invasive fungal infections low in spite of heavy fungal colonization. However, there may be a risk of emergence of resistant fungal strains.</description><identifier>ISSN: 0195-6701</identifier><identifier>EISSN: 1532-2939</identifier><identifier>DOI: 10.1053/jhin.1999.0718</identifier><identifier>PMID: 10973747</identifier><language>eng</language><publisher>Kent: Elsevier</publisher><subject>Amphotericin B - pharmacology ; Antifungal Agents - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; azoles ; Biological and medical sciences ; Candida ; Cross Infection - epidemiology ; Cross Infection - prevention &amp; control ; Drug Resistance, Microbial ; Female ; Finland - epidemiology ; Fluconazole - pharmacology ; Hematologic and hematopoietic diseases ; Hematologic Neoplasms - complications ; Hematologic Neoplasms - drug therapy ; Hospital Units ; Humans ; Infection Control ; Itraconazole - pharmacology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Mycoses - epidemiology ; Mycoses - prevention &amp; control ; Neutropenia - chemically induced ; Neutropenia - complications ; Saccharomyces cerevisiae ; Saccharomyces cerevisiae - drug effects ; Saccharomyces cerevisiae - isolation &amp; purification</subject><ispartof>The Journal of hospital infection, 2000-08, Vol.45 (4), p.293-301</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1490923$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10973747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SALONEN, J. H</creatorcontrib><creatorcontrib>RICHARDSON, M. D</creatorcontrib><creatorcontrib>GALLACHER, K</creatorcontrib><creatorcontrib>ISSAKAINEN, J</creatorcontrib><creatorcontrib>HELENIUS, H</creatorcontrib><creatorcontrib>LEHTONEN, O.-P</creatorcontrib><creatorcontrib>NIKOSKELAINEN, J</creatorcontrib><title>Fungal colonization of haematological patients receiving cytotoxic chemotherapy : emergence of azole-resistant Saccharomyces cerevisiae</title><title>The Journal of hospital infection</title><addtitle>J Hosp Infect</addtitle><description>Fungal colonization during cytotoxic chemotherapy was studied in 42 patients with a recent diagnosis of a haematological malignancy. In total, 2759 surveillance cultures were taken from the nostrils, throat, urine, stool and perineal region. Seven hundred and ninety-six positive surveillance cultures (28.9%) yielded 968 fungal isolates. The rate of fungal colonization did not differ between patients with acute leukaemia, patients with other haematological malignancies and control patients in the same ward at admission (71% vs. 67% vs. 80%). Patients with acute leukaemia were colonized at a significantly lower rate in samples from the throat (32%), urine (10%), stool (45%) and perineum (29%) taken during hospitalization when compared with other haematological patients (respective values 58%, 21%, 67% and 45%; P-values 0.001). This could be attributed to differences in the use of antifungal drugs. Although 21/42 (50%) of our patients had multiple-site fungal colonization at the end of follow-up, only one systemic Candida infection was diagnosed. Extensive use of antifungal treatment may have influenced the low incidence of systemic fungal infections during the follow-up. In addition to Candida species, Malassezia furfur, Geotrichum candidum and Saccharomyces cerevisiae were frequently isolated. The rate of S. cerevisiae isolation increased significantly over time after admission (1%, vs. 18% of isolates, P&lt;0.001), suggesting hospital-acquired transmission. These isolates were highly resistant to azole antifungals (MIC90 128 microg/mL for fluconazole and 16 microg/ml, for itraconazole), and caused persistent multiple site colonization in 12 patients. Extensive use of antifungal agents in a haematological ward may keep the incidence of invasive fungal infections low in spite of heavy fungal colonization. However, there may be a risk of emergence of resistant fungal strains.</description><subject>Amphotericin B - pharmacology</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>azoles</subject><subject>Biological and medical sciences</subject><subject>Candida</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - prevention &amp; control</subject><subject>Drug Resistance, Microbial</subject><subject>Female</subject><subject>Finland - epidemiology</subject><subject>Fluconazole - pharmacology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematologic Neoplasms - complications</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Hospital Units</subject><subject>Humans</subject><subject>Infection Control</subject><subject>Itraconazole - pharmacology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Mycoses - epidemiology</subject><subject>Mycoses - prevention &amp; control</subject><subject>Neutropenia - chemically induced</subject><subject>Neutropenia - complications</subject><subject>Saccharomyces cerevisiae</subject><subject>Saccharomyces cerevisiae - drug effects</subject><subject>Saccharomyces cerevisiae - isolation &amp; purification</subject><issn>0195-6701</issn><issn>1532-2939</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkLFu2zAURYkiReO4XTMGHIJuckmTEsVsgRE3BQx0qHfjkXqyaEikQtJB7B_ob1dFHXS6wLkHd7iE3HK24KwU3w6d8wuutV4wxesPZMZLsSyWWugrMmNcl0WlGL8mNykdGGMTLz-Ra860EkqqGfm9Pvo99NSGPnh3huyCp6GlHeAAeYJ7Z6d6nAr0OdGIFt2r83tqTznk8OYstR0OIXcYYTzRB4oDxj16i3934Bx6LCImlzL4TH-BtR3EMJwsJmox4qtLDvAz-dhCn_DLJedku37arp6Lzc_vP1aPm2JcVioXlRECNGvqGhrRommZrHjTGGuMbCUDU5bctjXKRhtTSqUBaoFKSrSNUpWYk6__ZscYXo6Y8m5wyWLfg8dwTDuu6qpmik3i3UU8mgGb3RjdAPG0e39uEu4vAqTpoTaCty7996RmeinEH1rvgmk</recordid><startdate>20000801</startdate><enddate>20000801</enddate><creator>SALONEN, J. H</creator><creator>RICHARDSON, M. D</creator><creator>GALLACHER, K</creator><creator>ISSAKAINEN, J</creator><creator>HELENIUS, H</creator><creator>LEHTONEN, O.-P</creator><creator>NIKOSKELAINEN, J</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>M7N</scope></search><sort><creationdate>20000801</creationdate><title>Fungal colonization of haematological patients receiving cytotoxic chemotherapy : emergence of azole-resistant Saccharomyces cerevisiae</title><author>SALONEN, J. H ; RICHARDSON, M. D ; GALLACHER, K ; ISSAKAINEN, J ; HELENIUS, H ; LEHTONEN, O.-P ; NIKOSKELAINEN, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p267t-6b33a90d88ad3febf0461ddbcbb4f40ab551cf8e4d9bb5479aa83e744ecd7763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amphotericin B - pharmacology</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>azoles</topic><topic>Biological and medical sciences</topic><topic>Candida</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - prevention &amp; control</topic><topic>Drug Resistance, Microbial</topic><topic>Female</topic><topic>Finland - epidemiology</topic><topic>Fluconazole - pharmacology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematologic Neoplasms - complications</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Hospital Units</topic><topic>Humans</topic><topic>Infection Control</topic><topic>Itraconazole - pharmacology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Mycoses - epidemiology</topic><topic>Mycoses - prevention &amp; control</topic><topic>Neutropenia - chemically induced</topic><topic>Neutropenia - complications</topic><topic>Saccharomyces cerevisiae</topic><topic>Saccharomyces cerevisiae - drug effects</topic><topic>Saccharomyces cerevisiae - isolation &amp; purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SALONEN, J. H</creatorcontrib><creatorcontrib>RICHARDSON, M. D</creatorcontrib><creatorcontrib>GALLACHER, K</creatorcontrib><creatorcontrib>ISSAKAINEN, J</creatorcontrib><creatorcontrib>HELENIUS, H</creatorcontrib><creatorcontrib>LEHTONEN, O.-P</creatorcontrib><creatorcontrib>NIKOSKELAINEN, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>The Journal of hospital infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SALONEN, J. H</au><au>RICHARDSON, M. D</au><au>GALLACHER, K</au><au>ISSAKAINEN, J</au><au>HELENIUS, H</au><au>LEHTONEN, O.-P</au><au>NIKOSKELAINEN, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fungal colonization of haematological patients receiving cytotoxic chemotherapy : emergence of azole-resistant Saccharomyces cerevisiae</atitle><jtitle>The Journal of hospital infection</jtitle><addtitle>J Hosp Infect</addtitle><date>2000-08-01</date><risdate>2000</risdate><volume>45</volume><issue>4</issue><spage>293</spage><epage>301</epage><pages>293-301</pages><issn>0195-6701</issn><eissn>1532-2939</eissn><abstract>Fungal colonization during cytotoxic chemotherapy was studied in 42 patients with a recent diagnosis of a haematological malignancy. In total, 2759 surveillance cultures were taken from the nostrils, throat, urine, stool and perineal region. Seven hundred and ninety-six positive surveillance cultures (28.9%) yielded 968 fungal isolates. The rate of fungal colonization did not differ between patients with acute leukaemia, patients with other haematological malignancies and control patients in the same ward at admission (71% vs. 67% vs. 80%). Patients with acute leukaemia were colonized at a significantly lower rate in samples from the throat (32%), urine (10%), stool (45%) and perineum (29%) taken during hospitalization when compared with other haematological patients (respective values 58%, 21%, 67% and 45%; P-values 0.001). This could be attributed to differences in the use of antifungal drugs. Although 21/42 (50%) of our patients had multiple-site fungal colonization at the end of follow-up, only one systemic Candida infection was diagnosed. Extensive use of antifungal treatment may have influenced the low incidence of systemic fungal infections during the follow-up. In addition to Candida species, Malassezia furfur, Geotrichum candidum and Saccharomyces cerevisiae were frequently isolated. The rate of S. cerevisiae isolation increased significantly over time after admission (1%, vs. 18% of isolates, P&lt;0.001), suggesting hospital-acquired transmission. These isolates were highly resistant to azole antifungals (MIC90 128 microg/mL for fluconazole and 16 microg/ml, for itraconazole), and caused persistent multiple site colonization in 12 patients. Extensive use of antifungal agents in a haematological ward may keep the incidence of invasive fungal infections low in spite of heavy fungal colonization. However, there may be a risk of emergence of resistant fungal strains.</abstract><cop>Kent</cop><pub>Elsevier</pub><pmid>10973747</pmid><doi>10.1053/jhin.1999.0718</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0195-6701
ispartof The Journal of hospital infection, 2000-08, Vol.45 (4), p.293-301
issn 0195-6701
1532-2939
language eng
recordid cdi_proquest_miscellaneous_17868070
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Amphotericin B - pharmacology
Antifungal Agents - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
azoles
Biological and medical sciences
Candida
Cross Infection - epidemiology
Cross Infection - prevention & control
Drug Resistance, Microbial
Female
Finland - epidemiology
Fluconazole - pharmacology
Hematologic and hematopoietic diseases
Hematologic Neoplasms - complications
Hematologic Neoplasms - drug therapy
Hospital Units
Humans
Infection Control
Itraconazole - pharmacology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Microbial Sensitivity Tests
Middle Aged
Mycoses - epidemiology
Mycoses - prevention & control
Neutropenia - chemically induced
Neutropenia - complications
Saccharomyces cerevisiae
Saccharomyces cerevisiae - drug effects
Saccharomyces cerevisiae - isolation & purification
title Fungal colonization of haematological patients receiving cytotoxic chemotherapy : emergence of azole-resistant Saccharomyces cerevisiae
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fungal%20colonization%20of%20haematological%20patients%20receiving%20cytotoxic%20chemotherapy%20:%20emergence%20of%20azole-resistant%20Saccharomyces%20cerevisiae&rft.jtitle=The%20Journal%20of%20hospital%20infection&rft.au=SALONEN,%20J.%20H&rft.date=2000-08-01&rft.volume=45&rft.issue=4&rft.spage=293&rft.epage=301&rft.pages=293-301&rft.issn=0195-6701&rft.eissn=1532-2939&rft_id=info:doi/10.1053/jhin.1999.0718&rft_dat=%3Cproquest_pubme%3E17868070%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17868070&rft_id=info:pmid/10973747&rfr_iscdi=true